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Ørjan Samuelsen1,10 and Arnfinn Sundsfjord1,11* on behalf of the NordicAST CPE Study Group†
1Norwegian National Advisory Unit on Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control,
University Hospital of North Norway, Tromsø, Norway; 2Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden;
3Department of Clinical Microbiology, Herlev and Gentofte Hospital, Herlev, Denmark; 4Department of Clinical Microbiology, Landspitali
University Hospital, Reykjavik, Iceland; 5EUCAST Development Laboratory, Växjö, Sweden; 6Department of Medical Microbiology,
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Objectives: To examine performance of EUCAST disc diffusion and supplementary MIC methods for detection of
Enterobacteriaceae with reduced susceptibility to meropenem using EUCAST screening recommendations.
Methods: Sixty-one Nordic laboratories delivered data on EUCAST disc diffusion (n"61), semi-automated mero-
penem MIC (n"23; VITEK2, n"20 and Phoenix, n"3) and gradient meropenem MIC (n"58) methods.
The strains (n"27) included the major carbapenemase classes (A, n"4; B, n"9; D, n"6) involved in the global
spread of carbapenemase-producing Enterobacteriaceae (CPE) and non-CPE strains (n"8) covering a range of
broth microdilution (BMD) meropenem MICs.
Results: A triplicate Klebsiella variicola (meropenem MIC 0.5 mg/L) harbouring OXA-48 and Escherichia coli ATCC
25922 showed an overall good precision. Meropenem zone diameters below the EUCAST screening cut-off
(,27 mm) were reported for strains with MIC 1 mg/L (n"21), irrespective of resistance mechanism. For three
strains (MIC"0.5 mg/L) with OXA-48/-181, eight laboratories provided meropenem zone diameters above the
screening cut-off. Very major errors (VMEs) were not observed. The overall distributions of major errors (MEs) and
minor errors (mEs) were 9% and 36% (disc diffusion), 26% and 18% (VITEK2) and 7% and 20% (gradient MIC),
respectively. Differences in ME and mE distributions between disc diffusion and MIC gradient tests compared
with semi-automated methods were significant (P , 0.0001), using BMD MICs as a reference for categorization.
Conclusions: The EUCAST disc diffusion method is a robust method to screen for CPE but isolates with merope-
nem MICs ,1 mg/L pose challenges. The high ME rate in semi-automated methods might deter appropriate use
of carbapenems in CPE infections with limited therapeutic options.
Introduction
With ever-increasing antimicrobial resistance, accurate and
rapid antimicrobial susceptibility testing (AST) is essential for
implementing appropriate therapy and timely infection control
measures. This is particularly relevant when infections are caused
by MDR Enterobacteriaceae, for which carbapenems remain a
crucial therapeutic option.
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The efficacy of carbapenems is jeopardized by the global
increase in carbapenem-resistant Enterobacteriaceae (CRE).1–5
Molecular mechanisms of carbapenem resistance in Enterobacter-
iaceae can be framed in two categories, which are not mutually
exclusive:6,7 (i) combined synergy between ESBLs and/or AmpC
cephalosporinases (AmpC) and chromosomal mutations media-
ting porin deficiency, drug efflux and/or alterations in PBPs; and
(ii) carbapenem hydrolysis by acquired carbapenemase enzymes.
Carbapenemase-producing Enterobacteriaceae (CPE) have trans-
missible carbapenem resistance as the carbapenemase-encoding
genes are mostly located on mobile genetic elements, a key factor
in their global spread.5 Particular CPE are now endemic in many
parts of the world, including European countries such as Greece,
Italy and Romania.8
The worldwide distribution of acquired carbapenemases in clin-
ical strains of Enterobacteriaceae is dominated by five families
within three Ambler classes: KPC (class A), NDM, VIM and IMP (class
B) and OXA-48-like (class D).5,8 This is consistent with the situation
in the Nordic countries.9–14 The phenotypic expression of carbape-
nemase production in terms of carbapenem MICs varies with
species, strain and enzyme characteristics.4,15–17 NDM-/KPC-pro-
ducing strains of Enterobacteriaceae are mostly associated with
moderate to high meropenem MICs.15,16,18 In contrast, OXA-48-
like-producing Enterobacteriaceae, Escherichia coli in particular,
exhibit lower carbapenem MICs due to their relatively weak carba-
penemase activity.15,17–20 However, in combination with perme-
ability deficiencies, OXA-48-like CPE may express high-level
carbapenem resistance.19,20 The diversity in carbapenem MIC dis-
tribution among CPE strains challenges the performance and inter-
pretation of current phenotypic antimicrobial susceptibility tests.
Various carbapenems have been evaluated for optimal detection
of CPE, and meropenem seems to provide the best balance be-
tween sensitivity and specificity for screening purposes.21
Screening recommendations for detection of CPE are provided
by CLSI and EUCAST, but optimal screening cut-offs are the subject
of debate and may depend on local epidemiology. A recent study
of clinical isolates of Enterobacteriaceae (n"1022) submitted to a
reference laboratory for confirmation of carbapenemase produc-
tion (n"188/1022; 18.4%) showed that 14% and 1.6% of the CPE
isolates would have been missed by CLSI and EUCAST screening
breakpoints, respectively.15
The objective of this study was to examine the performance of
the EUCAST disc diffusion method and supplementary MIC meth-
ods in detection of Enterobacteriaceae with reduced susceptibility
to meropenem in a multicentre format using the EUCAST screen-
ing recommendations. We invited all Nordic clinical microbiology
laboratories to blindly examine a well-characterized, genetically
diverse collection of carbapenemase- and non-carbapenemase-
producing clinical isolates of Enterobacteriaceae with reduced sus-
ceptibility to meropenem (non-WT; MIC .0.12 mg/L).
Materials and methods
Study design
The study was organized through the Nordic Committee on Antimicrobial
Susceptibility Testing (NordicAST) network (www.nordicast.org). All Danish
(n"11), Finnish (n"24), Icelandic (n"1), Norwegian (n"22) and Swedish
(n"26) clinical microbiology laboratories were invited. The study protocol
included: (i) bacterial identification and recording of methods; (ii) AST by the
EUCAST disc diffusion method using the following panel: meropenem
(10lg), cefotaxime (5 lg), ceftazidime (10lg) and piperacillin/tazobactam
(30/6lg); (iii) meropenem MIC determination using broth microdilution and/
or an MIC gradient strip test; (iv) reporting of AST results from semi-
automated AST devices by those laboratories routinely using them; (v) inter-
pretation of results using the NordicAST algorithm based on the EUCAST
2013 guidelines,22 which were operational during the study period; and (vi)
reporting of inhibition zone diameters, meropenem MIC, clinical breakpoint
interpretation (SIR) and potential carbapenemase production (yes/no). The
laboratories were asked to carry out the analyses as part of their routine
diagnostic workflow. Genotypic confirmative testing was not allowed.
For detection of CPE, the EUCAST 2013 guidelines recommended
screening cut-offs using meropenem MIC .0.12 mg/L and/or a , 25 mm
meropenem (10lg) disc diffusion zone diameter, with an increased mero-
penem zone diameter cut-off (the EUCAST screening cut-off) of ,27 mm
recommended for areas where OXA-48 producers are endemic. Notably,
the meropenem EUCAST screening cut-off is different to the clinical break-
point used for categorization of meropenem susceptibility. The operational
NordicAST algorithm recommended that Enterobacteriaceae with merope-
nem zone diameters of 25–26 mm and piperacillin/tazobactam interpreted
as intermediate or susceptible (unlikely OXA-48 producers) did not require
carbapenemase confirmation tests.
Comparison of methods was carried out with meropenem broth microdilu-
tion (BMD) as the reference method. Performance criteria were calculated
according to ISO 20776-2 (https://www.iso.org/obp/ui/#iso:std:iso:20776:-2:ed-
1:v1:en) based on EUCAST clinical breakpoints v.6.0, which remain valid for
meropenem. Essential agreement (EA), categorical agreement (CA), very
major error (VME), major error (ME) and minor error (mE) rates were calculated.
Strain collection
The strain collection (Table 1) consisted of carbapenemase-positive
(n"19) and carbapenemase-negative (n"8) clinical isolates of
Enterobacteriaceae with reduced susceptibility to meropenem (MIC range
0.25 to 16 mg/L) obtained during 2007–14. Reference MICs were deter-
mined using BMD (Sensititre, Trek Diagnostic Systems, Cleveland, USA).
E. coli ATCC 25922 was used as a meropenem-susceptible quality control
(QC) strain. The carbapenemase-positive isolates were selected from a pre-
viously characterized Norwegian strain collection, mostly associated with
import.10 The carbapenemase-negative isolates were characterized as part
of this study. All strains were identified by MALDI-TOF MS (Bruker Daltonik,
Bremen, Germany) and characterized by WGS as described previously.10
Carbapenemase-encoding resistance genes were determined using
ResFinder (https://cge.cbs.dtu.dk/services/ResFinder/) and MLST was per-
formed using the CGE MLST server (https://cge.cbs.dtu.dk/services/MLST/).
The clinical strains included Klebsiella spp. (n"11), E. coli (n"7),
Enterobacter spp. (n"5), Citrobacter sp. (n"1), Proteus mirabilis (n"2)
and Providencia rettgeri (n"1). The carbapenemases included: class A,
blaKPC (n"3) and blaIMI (n"1); class B, blaNDM (n"5), blaVIM (n"3) and
blaIMP (n"1); and class D, blaOXA-48-like (n"6). One blaOXA-48-positive
Klebsiella variicola (meropenem MIC 0.5 mg/L) was provided in triplicate
and one Klebsiella pneumoniae isolate harboured both blaNDM and blaOXA-
181. The strains covered a range of meropenem MICs: 0.25 mg/L (n"2),
0.5 mg/L (n"6; including the triplicate), 1.0 mg/L (n"5), 2.0 mg/L (n"5),
4.0 mg/L (n"3), 8.0 mg/L (n"4) and16 mg/L (n"4).
QC
QC assessment was based on EUCAST QC tables.23
Statistical analysis
Differences in categorical and continuous data between groups were
examined by v2 tests and t-tests, respectively. P , 0.05 was considered
significant.
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Results
Participation
Sixty-one laboratories (73%), from Denmark (n"9; 82%), Finland
(n"15; 63%), Iceland (n"1; 100%), Norway (n"14; 64%) and
Sweden (n"22; 85%), delivered data on bacterial identification
(n"61), EUCAST disc diffusion (n"61), meropenem MIC (n"60)
and semi-automated AST (n"23; 38%).
Bacterial identification
All but one of the isolates were correctly identified to genus level.
Minor discrepancies were observed in identification to species level.
Most laboratories (n"56; 92%) used MALDI-TOF MS for identifica-
tion; MALDI Biotyper (n"44; Bruker Daltonik) and VITEK MS
(n"12; bioMérieux, Marcy l’Étoile, France). Five laboratories (8%)
used VITEK2 (bioMérieux) and/or API20E (bioMérieux).
Materials for AST
Disc manufacturers included BD (n"3; Becton Dickinson, NY,
USA), MAST (n"5; MAST Group, Bootle, UK), Oxoid (n"50; Oxoid,
Basingstoke, UK) and ROSCO (n"3; ROSCO Diagnostica,
Taastrup, Denmark). Suppliers of Mueller–Hinton agar (MHA)
included BD (n"20), Bio-Rad (n"1; Bio-Rad Clinical Diagnostics,
Oslo, Norway), E&O labs (n"1; E&O laboratories Ltd, UK), Lab M
(n"2; Lab M Ltd, UK) and Oxoid (n"37). Meropenem MIC deter-
mination was performed using gradient strips (n"58), in-house
BMD (n"1) or commercial BMD (n"1; Sensititre). MIC gradients
included Etest (n"34; bioMérieux), MIC Test strip (MTS) (n"18;
Liofilchem, Italy) or M.I.C.Evaluator (M.I.C.E.) (n"6; Oxoid).
Table 1. Bacterial strains (n"27) used in this study and their relevant characteristics
Carbapenemase class/species Meropenem MIC (mg/L) Carbapenemases Other b-lactamases Isolate no.
Class A (serine) (n"4)
K. pneumoniae 1 KPC-2 SHV-11; TEM-1 4
E. cloacae complex 16 KPC-2 CTX-M-15; OXA-1; TEM-1 19
E. cloacae complex 8 KPC-2 ACT-6[va]; OXA-9-pb; TEM-1 28
E. cloacae complex 1 IMI-9 ACT[v] 3
Class B (MBL) (n"9)
K. pneumoniae 16 NDM-1!OXA-181d CTX-M-15; OXA-1; SHV-11; TEM-1 2
K. pneumoniae 16 NDM-1 CTX-M-15; CMY-6; OXA-1; SHV-11 5
P. mirabilis 0.25 NDM-1 CMY-16; OXA-10 8
E. coli 2 NDM-5 SHV-12; TEM-1 9
Citrobacter sp. 4 NDM-1 CMY-4; OXA-10; SED-1 11
E. coli 1 VIM-29 CTX-M-15; CMY-4; OXA-1 7
K. pneumoniae 2 VIM-1 SHV-12 27
K. pneumoniae 16 VIM-27 SHV-11 29
E. coli 1 IMP-26 CTX-M-15; TEM-1 24
Class D (OXA-48-like) (n"6c)
K. variicolac 0.5 OXA-48 LEN-16 6, 10, 25
K. pneumoniae 2 OXA-48 CTX-M-15; OXA-1; SHV-76; TEM-1 1
K. pneumoniae 0.5 OXA-48 SHV-11 14
E. coli 1 OXA-48 CTX-M-24; TEM-1 17
E. coli 0.5 OXA-181d CTX-M-15; CMY-2; OXA-1; TEM-1 23
K. pneumoniae 2 OXA-162d CTX-M-15, SHV-100, TEM-1 26
CPE-negative (n"8)
K. pneumoniae 4 — CTX-M-15; SHV-11; OXA-1 12
E. coli 8 — CMY-42; OXA-1; TEM-1 13
K. pneumoniae 4 — CTX-M-15; OXA-1; SHV-27 15
E. cloacae complex 0.25 — ACT-15 16
E. coli 8 — CTX-M-15; OXA-1 18
P. mirabilis 0.5 — — 20
Enterobacter aerogenes 8 — — 21
P. rettgeri 2 — PER-1 22
av" variant gene.
bp"partial gene.
cThe K. variicola strain was provided in triplicate.








/jac/article-abstract/73/10/2738/5058071 by Landspitalinn user on 11 January 2019
Twenty-three laboratories performed semi-automated AST
including VITEK2 AST (n"20; bioMérieux) and Phoenix (n"3;
BD). VITEK2 panels included: AST-N230 (n"6), AST-N218 (n"5)
and AST-N209 (n"9). The Phoenix NMIC-93 (n"2) and 25
NMIC/ID90 (n"1) panels were used.
QC
All laboratories except one reported meropenem zone diameters
in agreement with the accepted QC range for E. coli ATCC 25922
(28–35 mm), with 25 laboratories (42%) on target values (31–
32 mm), with no significant differences in zone diameters between
Oxoid and BD MHA (P"0.6). For the discs, no formal statistical test-
ing was possible due to a limited number of comparative observa-
tions. For piperacillin/tazobactam, cefotaxime and ceftazidime,
93%, 97% and 98% of the laboratories, respectively, reported zone
diameters in agreement with the accepted QC range for E. coli
ATCC 25922. All except two laboratories (3%) reported merope-
nem MICs within the accepted QC range for E. coli ATCC 25922
(0.008–0.06 mg/L), with 55 laboratories (92%) on target values
(0.016–0.03 mg/L).
There was good reproducibility (precision) for the OXA-48-
producing K. variicola triplicate with 59/61 laboratories reporting
meropenem zone diameters within 5 mm. A total of 60 laborato-
ries performed 180 MIC tests on this triplicate with a median MIC
value of 0.5 mg/L. Of these, 109 (61%) were on the target value
(0.5 mg/L) or within 0.25–1 mg/L (which equals target +1 dilu-
tion). Twenty-one of 60 laboratories (35%) obtained a value within
this range on all three occasions. For the most commonly used
methods, 34, 18 and 6 laboratories used Etest, MTS and M.I.C.E., re-
spectively. Of these, 12 of 34 (35%), 5 of 18 (28%) and 3 of 6
(50%), respectively, obtained a value within the range on all tripli-
cates. Fifteen results (8%) were outside the target of+2 dilutions.
Performance of the EUCAST disc diffusion method in
detection of reduced susceptibility to meropenem
The results are based on the observations (n"1566) displayed in
Table 2 and those obtained with ROSCO tablets (n"81; Table S1,
available as Supplementary data at JAC Online); a total of 1647
observations, counting the K. variicola triplicate only once. ROSCO
tablets have a larger diameter (9 mm) than BD, MAST and Oxoid
discs (6 mm) and are therefore presented separately.
For strains with meropenem MIC1 mg/L (n"21), all laborato-
ries reported meropenem zone diameters below the EUCAST
screening cut-off, irrespective of resistance mechanism (with one
exception; isolate 18). For strains with a meropenem MIC of 0.25 or
0.5 mg/L, one or several (range 8–60) laboratories reported mero-
penem zone diameters above the EUCAST screening cut-off, also
affecting the interpretation of OXA-48-like carbapenemase
strains.
CA between meropenem disc diffusion results compared
with BMD meropenem MIC using EUCAST clinical
breakpoints for categorization
Zone diameters (n"1566) from individual laboratories (n"58)
using BD, MAST and Oxoid discs and corresponding SIR categories
(Table 2) plus observations from three laboratories using ROSCO
tablets (n"81 observations) were compared with the SIR cat-
egory as defined by the actual BMD meropenem MIC (Table 3). The
overall CA was 55%. No VMEs were observed. The overall propor-
tions of MEs and mEs were 9% and 36%, respectively, varying be-
tween Ambler classes and carbapenemase-negative strains.
Reporting potential carbapenemase production
(Table 4)
Forty-four laboratories (72%) interpreted their results using the
recommended EUCAST screening cut-off, taking into account the
piperacillin/tazobactam susceptibility profile. Notably, eight labo-
ratories (13%) used a ,25 mm cut-off and seven laboratories
(11%) interpreted the potential presence of carbapenemase pro-
duction according to clinical breakpoints. Two laboratories did not
report their interpretation criteria and were excluded from the
analysis.
Among the class A carbapenemase-producing strains (n"4),
the three blaKPC-positive strains were classified as potential carba-
penemase producers by 98%–100% of the laboratories. The
blaIMI-positive Enterobacter cloacae complex strain (median mero-
penem zone diameter 18 mm) was not reported as a carbapene-
mase producer by seven laboratories (11%).
Eight of the class B carbapenemase-positive isolates (n"9)
were interpreted as possible carbapenemase producers by 97%–
100% of the laboratories. Fifteen laboratories (25%) did not report
the blaNDM-positive P. mirabilis (median meropenem zone diam-
eter of 22 mm) as a putative carbapenemase producer.
The triplicate OXA-48-producing K. variicola isolates were not
classified as potential carbapenemase producers by 11 (18%),
10 (16%) and 12 (20%) laboratories, respectively. The median
meropenem zone diameters were 24, 23 and 24 mm, respectively.
It is notable that 2%–5% of the laboratories using the EUCAST
screening cut-off, 13%–38% of those using ,25 mm and 86% of
those using the clinical breakpoints did not suspect carbapene-
mase production in the K. variicola triplicate.
For the other OXA-48-like producers (n"5) with a meropenem
median zone diameter ranging between 20 and 24 mm,
80%–98% of the laboratories suspected carbapenemase produc-
tion. As for the triplicate strain, failure proportions in suspecting
carbapenemase production depended on the screening criteria
used.
Among the carbapenemase-negative strains (n"8), six were
suspected as carbapenemase producers by 90%–98% of the
laboratories. The E. cloacae complex strain (meropenem MIC
0.25 mg/L) was suspected to be a carbapenemase producer by 13
(21%) of the laboratories, while none suspected carbapenemase
production in the P. mirabilis strain (meropenem MIC 0.5 mg/L).
The median meropenem zone diameters for these two strains
were 28 and 30 mm, respectively.
Agreement between meropenem MIC measured by BMD
and semi-automated susceptibility testing
We recorded MIC observations using VITEK2 (n"539) and Phoenix
(n"81) from 20 and 3 laboratories, respectively (Table 3). The
overall EA between BMD and VITEK2 was 65%. Fifty percent, 61%
and 25% of the MICs from the VITEK2 systems were higher (.2-
fold) than the BMD MIC for class A, class B and class D
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carbapenemase-producing strains, respectively. Notably, labora-
tories did not report lower VITEK2 meropenem MICs compared
with BMD for carbapenemase producers, in contrast to
carbapenemase-negative strains.
Overall CA between BMD and VITEK2 was 56%. No VMEs were
observed. Overall proportions of MEs and mEs were 26% and 18%,
respectively, varying with resistance mechanism. No MEs were
observed for carbapenemase-negative strains. The difference in
distributions of MEs and mEs between disc diffusion and VITEK2
was statistically significant (P , 0.0001).
For the Phoenix system (n"81), MICs were higher than the
BMD MICs for the class A (25%), class B (44%) and class D (17%)
carbapenemase-producing strains (Table 3); none of the
carbapenemase-negative strains measured above the BMD MIC.
There was no statistical significant difference in overall results be-
tween VITEK2 and Phoenix (P"0.132).
Overall CA between BMD and Phoenix was 71% with no VMEs.
The total proportions of MEs and mEs were 14% and 15%, varying
between strains with different carbapenemase classes. No MEs
were reported for class D and carbapenemase-negative strains.
Agreement between meropenem MIC determined by
BMD and gradient tests
We recorded 1566 gradient MIC observations with Etest (n"918),
MTS (n"486) and M.I.C.E. strips (n"162), from 34, 18 and 6 labo-
ratories, respectively (Table S2). All class A and class B
carbapenemase-producing strains expressed gradient merope-
nem MIC above the EUCAST MIC screening cut-off value
(.0.12 mg/L). In contrast, 18 laboratories (18/60; 30%) reported
meropenem MIC below the EUCAST MIC screening cut-off value for
the triplicate strains of the OXA-48-producing K. variicola, all
reporting 0.125 mg/L. Nine laboratories (15%) reported merope-
nem MIC below the cut-off (0.125 mg/L) for three of the other
OXA-48-like strains. The median gradient test MIC for these strains
was 0.5 mg/L.
The meropenem MIC agreement between BMD and gradient
tests is presented in Table 3. Overall EA was 70%. In contrast to
VITEK2, the gradient tests did record meropenem MIC values
below the BMD reference MIC for class A, B and D carbapenemase-
producing strains. The overall results between VITEK2 and MIC gra-
dient tests were significantly different (P , 0.0001).
Table 3. Agreement (%) between meropenem MIC determined by BMD and disc diffusion, semi-automated susceptibility testing or gradient tests
and corresponding CA (%) in clinical SIR categorization
Method/no. of observations
Agreement categorya and n (%) of instances
Group EA .BMD MIC ,BMD MIC VME ME mE CA
Disc diffusion
1647 total NA NA NA 0 153 (9) 594 (36) 900 (55)
244 class A NA NA NA 0 48 (20) 117 (48) 79 (32)
549 class B NA NA NA 0 69 (13) 226 (41) 254 (46)
366 class D NA NA NA 0 26 (7) 114 (31) 226 (62)
488 CPE-negative NA NA NA 0 10 (2) 137 (28) 341 (70)
Automated ASTs
VITEK2
539 total 347 (65) 180 (33) 12 (2) 0 141 (26) 98 (18) 300 (56)
80 class A 40 (50) 40 (50) 0 0 40 (50) 20 (25) 20 (25)
179 class B 69 (39) 110 (61) 0 0 98 (55) 12 (7) 69 (38)
120 class D 90 (75) 30 (25) 0 0 3 (2.5) 34 (28) 83 (69.5)
160 CPE-negative 148 (92.5) 0 12 (7.5) 0 0 32 (20) 128 (80)
Phoenix
81 total 61 (75) 18 (22) 2 (3) 0 11 (14) 12 (15) 58 (71)
12 class A 9 (75) 3 (25) 0 0 2 (16) 2 (16) 8 (68)
27 class B 14 (52) 12 (44) 1 (4) 0 9 (33) 4 (15) 14 (52)
18 class D 15 (83) 3 (17) 0 0 0 3 (17) 15 (83)
24 CPE-negative 23 (96) 0 1 (4) 0 0 3 (12.5) 21 (87.5)
MIC gradient testsb
1566 total 1105 (70) 278 (18) 183 (12) 0 114 (7) 319 (20) 1133 (73)
232 class A 161 (69) 65 (28) 6 (3) 0 40 (17) 64 (28) 128 (55)
522 class B 384 (74) 122 (23) 16 (3) 0 43 (8) 99 (19) 380 (73)
348 class D 226 (65) 54 (15.5) 68 (19.5) 0 12 (3) 28 (8) 308 (89)
464 CPE-negative 334 (72) 36 (8) 94 (20) 0 19 (4) 128 (28) 317 (68)
NA, not applicable.
aEA, results within one 2-fold MIC dilution; CA, agreement in SIR category; VME, false susceptibility; ME, false resistance; mE, susceptible or resistant
interpreted as intermediate or vice versa.
bMIC gradient tests from bioMérieux (n"34), Liofilchem (n"18) and Oxoid (n"6).
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Overall CA between BMD and gradient tests was 73%. No
VMEs were observed. The overall proportions of MEs and mEs
were 7% and 20%, varying between strains with different resist-
ance mechanisms. The difference in distributions of MEs and mEs
between MIC gradient tests and VITEK2 was significant
(P , 0.0001).
Discussion
Accurate detection of CPE is essential to prevent further transmis-
sion. We have examined the multicentre performance of EUCAST
disc diffusion and selected MIC methods in detection of
Enterobacteriaceae with reduced meropenem susceptibility
involving 61 Nordic clinical laboratories. The strains included the
major bacterial species and carbapenemase classes involved in
the global spread of CPE, as well as non-CPE strains, representing a
range of meropenem MIC levels challenging the sensitivity and in-
terpretation of the methods involved.
The overall results suggest that the EUCAST disc diffusion
method is robust in detection of reduced susceptibility to merope-
nem in both CPE and non-CPE. No VMEs were observed and a rela-
tively low overall ME rate (9%) compared with semi-automated
systems (14%–26%), but in line with gradient tests (7%), was
found. However, a relatively high mE rate (36%) related to semi-
automated systems (15%–18%) and gradient tests (20%) was
noted.
Table 4. Reporting potential carbapenemase production from the laboratories (n"59) based on the use of different meropenem zone diameter





,27 mm (n"44)a ,25 mm (n"8) ,22 mm (n"7)
Carbapenemase Isolate no. Species yes (%) no (%) yes (%) no (%) yes (%) no (%)
Class A (serine)
KPC (n"3) 4 K. pneumoniae 1 98 100 0 87 13 100 0
19 E. cloacae complex 16 100 100 0 100 0 100 0
28 E. cloacae complex 8 98 98 2 100 0 100 0
IMI (n"1) 3 E. cloacae complex 1 89 95 5 62 38 86 14
Class B (MBL)
NDM (n"5) 2 K. pneumoniae 16 100 100 0 100 0 100 0
5 K. pneumoniae 16 100 100 0 100 0 100 0
8 P. mirabilis 0.25 75 89 11 75 25 14 86
9 E. coli 2 100 100 0 100 0 100 0
11 Citrobacter sp. 4 98 100 0 100 0 100 0
VIM (n"3) 7 E. coli 1 98 100 0 100 0 86 14
27 K. pneumoniae 2 98 100 0 100 0 100 0
29 K. pneumoniae 16 100 100 0 100 0 100 0
IMP (n"1) 24 E. coli 1 97 100 0 100 0 86 14
Class D (OXA-48-like) (n"6) 6 K. variicolab 0.5 82 95 5 87 13 14 86
10 K. variicola 0.5 84 98 2 87 13 14 86
25 K. variicola 0.5 80 95 5 62 38 14 86
1 K. pneumoniae 2 98 100 0 100 0 100 0
14 K. pneumoniae 0.5 80 93 7 87 13 14 86
17 E. coli 1 89 98 2 100 0 29 71
23 E. coli 0.5 87 98 2 87 13 43 57
26 K. pneumoniae 2 85 95 5 100 0 29 71
CPE-negative (n"8) 12 K. pneumoniae 4 97 98 2 100 0 86 14
13 E. coli 8 95 98 2 100 0 71 29
15 K. pneumoniae 4 98 98 2 100 0 100 0
16 E. cloacae complex 0.25 21 25 75 0 100 0 100
18 E. coli 8 95 98 2 87 13 86 14
20 P. mirabilis 0.5 0 0 100 0 100 0 100
21 E. aerogenes 8 93 95 5 100 0 100 0
22 P. rettgeri 2 90 95 5 100 0 71 29
MEM, meropenem.
aThe number shown is the number of laboratories.
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Meropenem zone diameters below the EUCAST screening cut-
off were reported for all strains with meropenem MIC1 mg/L ir-
respective of resistance mechanism. However, the sensitivity of
the EUCAST disc diffusion method is challenged by strains
expressing meropenem MICs ,1 mg/L. This observation is illus-
trated with the meropenem zone diameter range crossing the
screening breakpoint for all strains expressing BMD meropenem
MICs of 0.25–0.5 mg/L. Our results are consistent with previous
observations showing an overrepresentation of OXA-48-like CPE
strains within this low but significant non-WT MIC category.15,17
The results illustrate the challenges in setting appropriate
screening breakpoints for the detection of resistance mechanisms
of clinical importance. The breakpoints have to balance the need
for high sensitivity without compromising the predictive value of a
positive test result and must take into consideration variabilities in
the epidemiology of relevant carbapenemases. Thus, the EUCAST
2013 guidelines suggested increasing the zone diameter of the
meropenem CPE-screening breakpoint due to increased occur-
rence of OXA-48-like CPE.22 The present study was based on the
2013 EUCAST guidelines and supports the use of increased zone
diameters to enhance sensitivity in CPE detection. Our study design
did not allow assessment of specificity. The most recent EUCAST
guidelines have further increased the screening cut-off, now
including isolates with meropenem zone diameters of 25–27 mm
if they are also resistant to piperacillin/tazobactam and/or temocil-
lin.21 The addition of criteria linked to piperacillin/tazobactam and
temocillin resistance will contribute to higher specificity, particular-
ly in low CPE-prevalence settings, but the overall specificity
remains to be evaluated. Moreover, the screening methods are
continuously being challenged by new carbapenemase variants
with weak yet significant carbapenemase activity.24–26
A number of laboratories failed to report potential carbapene-
mase production in strains with meropenem MICs of 0.25–0.5 mg/L.
These failures were mainly due to the choice of screening break-
points and were most common in the OXA-48-like group, where
0%–86% of the laboratories using clinical breakpoints did not select
those strains for carbapenemase detection. In contrast, only 0%–
38% and 0%–7% of the laboratories using ,25 or ,27 mm as a
screening cut-off, respectively, did not suspect carbapenemase pro-
duction in the OXA-48-like group. Although the study protocol
referred to the NordicAST algorithm based on the EUCAST guide-
lines, several laboratories (n" 15) deviated from the recommenda-
tions for unknown reasons. It is not clear whether the variable
screening breakpoints used by laboratories was due to misinterpret-
ation of the study protocol or reflected local routine practice at the
time of the study. Nevertheless, our observations underline the im-
portance of clear communication in recommended screening
breakpoints to reduce the risk of misinterpretations.
We observed a significant trend towards overestimation of
meropenem MIC for CPE and a potential underestimation of mero-
penem MIC for non-CPE strains with reduced susceptibility to
meropenem in semi-automated systems compared with BMD.
The inflated meropenem MIC, particularly for strains with class
A and class B carbapenemases will lead to overcalling of resist-
ance. In the past this would perhaps not be seen as a significant
problem, due to the general approach of discouraging use of car-
bapenems. However, clinical studies have shown that, even when
MICs are elevated, carbapenems still have an important role in the
treatment of infections caused by CPE, usually in combination with
other active agents.27 Overcalling resistance may therefore dis-
courage what would be appropriate use of meropenem for CPE
that remain clinically susceptible to meropenem. In contrast, the
significant trend towards underestimating meropenem MICs for
non-CPE strains may encourage inappropriate use of meropenem
in supposedly susceptible strains. Notably, we recorded no VMEs in
the overall CA between meropenem MIC obtained by BMD and
semi-automated systems. In contrast to the semi-automated sys-
tems, we did not observe any statistically significant trends in over-
estimation or underestimation of gradient test MICs compared
with BMD. The overall CA and EA were high; 73% and 70%, respect-
ively. As for semi-automated systems, we observed no VMEs.
Significantly lower ME rates were observed for gradient test mero-
penem MIC as compared with semi-automated systems.
In summary, the EUCAST disc diffusion method is a robust
method to screen for CPE, but isolates with low meropenem MICs
(,1 mg/L) still pose challenges to laboratories, not least from the
perspective of interpreting guidelines correctly. This study supports
using an increased meropenem screening cut-off of ,27 mm to
achieve greater sensitivity. This is particularly important in the de-
tection of OXA-48-like producing isolates. Further expansion of the
zone diameter (,28 mm), as recommended in the EUCAST 2017
guidelines, may add to the increased sensitivity. However, the ef-
fect on specificity of new screening cut-offs remains to be deter-
mined and would be of high interest in low resistance prevalence
settings. Using BMD as the reference method, we noted an overall
higher EA and CA with gradient tests compared with semi-
automated AST. Furthermore, we observed an overestimation of
meropenem MIC for CPE when using semi-automated systems
compared with BMD, resulting in high ME rates for class A and class
B carbapenemase-producing strains. The tendency of semi-
automated systems to overcall meropenem resistance in CPE
might have the undesirable effect of deterring appropriate use of
carbapenems in the treatment of infections caused by MDR
Enterobacteriaceae with limited therapeutic options.
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